

ARTICLE

Received 7 Apr 2011 | Accepted 29 Sep 2011 | Published 8 Nov 2011

DOI: 10.1038/ncomms1522

# Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory responses

Tarun Kumar Bhatt<sup>1,\*</sup>, Sameena Khan<sup>1,\*</sup>, Ved Prakash Dwivedi<sup>2</sup>, Mudassir Meraj Banday<sup>1</sup>, Arvind Sharma<sup>1</sup>, Anmol Chandele<sup>1</sup>, Noelia Camacho<sup>3</sup>, Lluís Ribas de Pouplana<sup>4</sup>, Yang Wu<sup>5</sup>, Alister G. Craig<sup>5</sup>, Antti Tapani Mikkonen<sup>6</sup>, Alexander Gerd Maier<sup>6</sup>, Manickam Yogavel<sup>1</sup> & Amit Sharma<sup>1</sup>

Malaria infection triggers pro-inflammatory responses in humans that are detrimental to host health. Parasite-induced enhancement in cytokine levels correlate with malaria-associated pathologies. Here we show that parasite tyrosyl-tRNA synthetase (*PfTyrRS*), a housekeeping protein translation enzyme, induces pro-inflammatory responses from host immune cells. *PfTyrRS* exits from the parasite cytoplasm into the infected red blood cell (iRBC) cytoplasm, from where it is released into the extracellular medium on iRBC lysis. Using its ELR peptide motif, *PfTyrRS* specifically binds to and internalizes into host macrophages, leading to enhanced secretion of the pro-inflammatory cytokines TNF- $\alpha$  and IL-6. *PfTyrRS*-macrophage interaction also augments expression of adherence-linked host endothelial receptors ICAM-1 and VCAM-1. Our description of *PfTyrRS* as a parasite-secreted protein that triggers pro-inflammatory host responses, along with its atomic resolution crystal structure in complex with tyrosyl-adenylate, provides a novel platform for targeting *PfTyrRS* in anti-parasitic strategies.

<sup>1</sup> Structural and Computational Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Road, New Delhi 110 067, India. <sup>2</sup> Immunology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Road, New Delhi 110 067, India. <sup>3</sup> Institute for Research in Biomedicine (IRB), C/ Baldiri Reixac 15-21, 08028 Barcelona, Catalonia, Spain. <sup>4</sup> Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010 Barcelona, Catalonia, Spain. <sup>5</sup> Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. <sup>6</sup> Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne Victoria 3086, Australia. \*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to A.S. (email: amit.icgeb@gmail.com).


Aminoacyl-tRNA synthetases are ancient enzymes responsible for genetic code translation<sup>1</sup>. These ubiquitous enzymes attach amino acids onto cognate transfer RNAs during protein translation, and are divided into two classes based on their structural topology<sup>1,2</sup>. Class I synthetases, like tyrosyl-tRNA synthetase (TyrRS), are characterized by a Rossmann fold, and this class contains two conserved ATP-binding motifs (HIGH and KMSKS)<sup>3,4</sup>. Apart from their parent aminoacylation activity, several aminoacyl-tRNA synthetases perform non-canonical functions in transcriptional regulation, apoptosis, ribosomal RNA biogenesis, angiogenesis and cell signalling<sup>5–8</sup>. Human TyrRS is processed by an elastase enzyme yielding an amino-terminal TyrRS (also known as mini-TyrRS) and carboxy-terminal EMAPII-like domain<sup>9–13</sup>. The latter contains cell signalling activity whereas human mini-TyrRS mimics interleukin-8 (IL-8) to chemo-attract polymorphonuclear cells<sup>9–13</sup>. Human mini-TyrRS interacts with CXCR1/2 receptors and acts as an angiogenic cytokine using a motif called ELR (Glu-Leu-Arg) that it shares with IL-8 (Fig. 1a). For the human mini-TyrRS ELR motif to be functional, the intact human enzyme is required to undergo proteolytic cleavage, which results in the release of EMAPII domain and subsequent exposure of the ELR motif<sup>9–13</sup>.

*Plasmodium* parasites are the causative agents of malaria. It is estimated that >300 million clinical malaria cases occur annually, resulting in >1 million deaths<sup>14</sup>. Malaria-related deaths occur owing to a range of syndromes including acute anemia and/or cerebral/placental malaria<sup>14,15</sup>. Most malaria pathology results from an acute inflammatory spurt, followed by activation of the host immune system and dysregulated cytokine release<sup>14–18</sup>. Human patient studies and mouse malaria models have consistently suggested that infection by the malaria parasite triggers an increase in the levels of numerous pro-inflammatory agents including tumour necrosis factor (TNF- $\alpha$ ), interferon gamma (IFN- $\gamma$ ) and interleukin 6 (IL-6) in blood plasma<sup>19–21</sup>. Although pro-inflammatory cytokines have a major role in patho-physiology of malaria disease<sup>16–21</sup>, the molecular mechanisms of cytokine release from immune cells remains largely unclear. Until now, several parasite-derived molecular agents have been implicated in triggering cytokine release<sup>22–25</sup>, but parasite-secreted protein(s) that potentially trigger specific cytokine secretion from host immune cells are less well understood. It is critical to understand the pathways and mechanisms that lead to cytokine release in malaria as disease pathology, directly or indirectly, generally results from dysregulation of circulating TNF- $\alpha$  and IL-6 amounts<sup>22–25</sup>.

*Plasmodium falciparum* genome contains two copies of tyrosyl-tRNA synthetase-tyrosyl-tRNA synthetase 1 (hereafter *PfTyrRS*, Plasmodb ID = MAL8p1.125) and tyrosyl-tRNA synthetase 2 (hereafter *PfTyrRS*<sup>api</sup>, Plasmodb ID = PF11\_0181). *PfTyrRS* was predicted to be cytoplasmic whereas *PfTyrRS*<sup>api</sup> is probably targeted to the parasite apicoplast<sup>6</sup>. Here we have investigated the structural, immunological and spatial localization attributes of *PfTyrRS*. Our comprehensive analyses provide a platform for focusing on *PfTyrRS* as a new target for development of novel malaria intervention strategies.


## Results

***PfTyrRS* characterization and structure.** Bacterially overexpressed *PfTyrRS* was purified to homogeneity using affinity and gel-filtration chromatography, and the protein migrates as a dimer (Fig. 1b). *PfTyrRS* enzyme activity was confirmed using tRNAs obtained by *in vitro* transcription using T7 RNA polymerase (Fig. 1c)<sup>26–28</sup>. We determined the three-dimensional structure of *PfTyrRS* in complex with YAP (tyrosyl-adenylate) to a resolution of 2.2 Å (Fig. 2a,b; Table 1). The crystallographic asymmetric unit contains a canonical tyrosyl-tRNA synthetase dimer. Eighteen N-terminal and three C-terminal residues were not clearly defined in the electron density for each monomer. The overall fold of *PfTyrRS* is typical of class I synthetases<sup>3,4</sup> and comprises a catalytic domain (residues 18–260,



**Figure 1 | Tyrosyl tRNA synthetase domain organization and enzyme characterization.** (a) Domain organization of TyrRS from *P. falciparum*, human and yeast. The 21 residue N-terminal extension in *PfTyrRS* is shown in orange. The ELR motif is shown in red and in yeast TyrRS it is replaced by NYR. (b) Gel filtration curves show both wild-type *PfTyrRS* (solid blue line) and ELR/AAA mutant (dotted red line) proteins as dimers in solution. (c) Aminoacylation curves with (blue line) and without (red line) added native *PfTyrRS* and using *Pf*-tRNA<sup>Tyr</sup>.

Rossmann fold) and an anti-codon-binding domain (residues 261–370). Human mitochondrial and malaria parasite apicoplastic TyrRS belong to bacterial lineage, whereas human cytoplasmic TyrRS and *PfTyrRS* belong to a separate eukaryotic group<sup>6,29</sup> (Fig. 2c). Structural superposition of 292 C $\alpha$  atoms between *PfTyrRS* and human mini-TyrRS (Protein Data Bank, accession code 1N3L) gives an RMSD of  $\sim 1.9$  Å (sequence identity  $\sim 30\%$ ), whereas the RMSD between 144 C $\alpha$  atoms of *PfTyrRS* and mitochondrial *HsTyrRS* (PDB: 2PID) is  $\sim 2.5$  Å (sequence identity  $< 10\%$ ). In *PfTyrRS*, the solvent accessible buried surface area at dimer interface is  $\sim 1,337$  Å<sup>2</sup>, and its value is comparable with L-Tyr bound mini-*HsTyrRS* (1,380 Å<sup>2</sup>) but not with the unliganded mini-*HsTyrRS* (buried area of 1,531 Å<sup>2</sup>). In mini-*HsTyrRS* structure<sup>13</sup>, the adenosine binding pocket is empty and seems enlarged by



**Figure 2 | Crystal structure of *PfTyrRS*.** (a) *PfTyrRS*:Tyr-AMP (YAP) complex structure where the ELR, KMSKS and HIGH motifs are shown in red, yellow and orange, respectively. Bound YAP is shown in stick model (green). (b) Stereoview of the experimental electron density map ( $2|F_o|-|F_c|$ ) for a portion of the final atomic model. The map is contoured at 1.2  $\sigma$  level. (c) Sequence alignment between mini-*HsTyrRS* and *PfTyrRS*. Important motifs are highlighted in red boxes and the ELR motifs are marked. (d) A close-up view of KMSKS loop and active site region of *PfTyrRS* along with corresponding regions from cytoplasmic mini-*HsTyrRS* and mitochondrial *HsTyrRS* (with 5'-O-[N-(L-Tyrosyl) sulfamoyl] adenosine also known as YSA). The disordered KMSKS loop is shown as dotted lines in human structures and the bound substrate/analog is shown as sticks. (e) Structural alignment and ELR motifs in mini-*HsTyrRS* (purple), *PfTyrRS* (green) and *HsIL-8* (orange).

~3 Å on either side of the binding pocket whereas, in YSA (5'-O-[N-(L-Tyrosyl) sulfamoyl] adenosine)-bound mitochondrial *HsTyrRS*<sup>29</sup> and in YAP-bound *PfTyrRS*, the adenosine-binding pocket is tighter (Fig. 2d). In *PfTyrRS*, the key synthetase motif of KMSKS loop is highly ordered and close to the bound substrate at the active site, whereas, in both cytoplasmic and mitochondrial *HsTyrRS*, this is found to be disordered (Fig. 2d). We find several other key structural differences between mini-*HsTyrRS* and *PfTyrRS* (Fig. 2c,d). First, at the primary sequence level, *PfTyrRS* has an N-terminal 21 residue extension whose role is unclear (Fig. 1a). On the other hand, human cytoplasmic *TyrRS* has a C-terminal extension in the form of an EMAPII domain that undergoes proteolytic processing to reveal a host module more similar in size to *PfTyrRS*<sup>9-13</sup> (Fig. 1a). The most notable and intriguing feature of both the mini-*HsTyrRS* and *PfTyrRS* is presence of an ELR motif (Figs. 1a and 2e). This tri-peptide signature is present in, among others, cytokines like IL-8 (refs 9-13,30). As shown in Figure

2e, ELR motifs decorate the surfaces of IL-8, mini-*HsTyrRS* and *PfTyrRS*. Structural alignment of ELR motifs from these three reveals striking conformational conservation (RMSD < 1 Å). In *PfTyrRS*, the ELR motif resides on  $\alpha$ -helix 2 whereas, in mini-*HsTyrRS*, it is located at  $\alpha$ -helix 5 (Fig. 2e). In both *PfTyrRS* and mini-*HsTyrRS*, the ELR motif is significantly distal from aminoacylation sites (Fig. 2e). In full-length cytoplasmic *HsTyrRS*, the ELR motif is buried under the C-terminal EMAPII domain, and this motif is exposed after proteolytic cleavage<sup>9-13</sup>. In contrast, the *PfTyrRS* ELR motif is exposed in three-dimensional space and does not require processing for its surface display. Therefore, in the parasite enzyme the ELR tri-peptide is continually solvent accessible owing to its presence in a different part of the overall three-dimensional structure relative to human *TyrRS* (Fig. 2a,e). Subtle structural perturbations caused by single residue mutations near the ELR motif can activate procytokine activity of human *TyrRS*<sup>11</sup>. These data on human *TyrRS*<sup>11</sup> suggested that the twin attributes of cytokine trigger and



**Table 1 | Data collection and refinement statistics.**


Parameters	<i>PfTyrRS-YAP</i>
<b>Data collection</b>	
Space group	C2
Unit cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	137.5, 46.5, 141.3
$\alpha$ , $\beta$ , $\gamma$ (°)	90, 93.8, 90
Resolution (Å)	50.0–2.2
<i>R</i> <sub>merge</sub>	0.056 (0.405)
<i>I</i> / $\sigma$ ( <i>I</i> )	51.0 (4.8)
Completeness (%)	94.7 (82.2)
Redundancy	14.1 (9.8)
<b>Refinement</b>	
Resolution (Å)	50.0–2.2
No. of reflections	42,842
<i>R</i> <sub>work</sub> / <i>R</i> <sub>free</sub>	0.172/0.214
<b>No. of atoms</b>	
Protein (two molecules)	5,726
Ligand/waters	70/371
<b>B-factors (Å<sup>2</sup>)</b>	
Protein	57
Ligand/waters	39/61
<b>R.m.s. deviations</b>	
Bond lengths (Å)	0.007
Bond angles (°)	1.09

Values in parentheses are for highest-resolution shell.

aminoacylation can coexist in a tyrosyl-tRNA synthetase<sup>11</sup>. Indeed, our description of the parasite *PfTyrRS* provides an excellent natural example of a synthetase enzyme with constitutively active ELR motif (Fig. 2). Interestingly, the ELR motif is absent in TyrRSs from lower eukaryotes and prokaryotes (Fig. 1a), again suggesting that ELR motif is independent of the parent aminoacylation activity of these enzymes.

Structural comparisons suggest sequence differences in 11 key residues that contribute to L-Tyr binding (5 residues) and adenosine binding (6 residues) between human and parasite enzymes (Fig. 2c,d). Residues in the conserved HIGH and KMSKS motifs are different between *PfTyrRS* (HIAQ and KMSKS) and mini-*HsTyrRS* (HAVY and KMSSS). In the L-Tyr bound mini-*HsTyrRS*, a K<sup>+</sup> ion is bound near adenine binding pocket whereas this space is empty in unliganded state of mini-*HsTyrRS*. In *PfTyrRS*, there is no density for an ion like K<sup>+</sup>, and further the residues involved in K<sup>+</sup> ion coordination in mini-*HsTyrRS* are not conserved in *PfTyrRS*. Therefore, several subtle yet crucial differences between host and pathogen tyrosyl-tRNA synthetase active sites (Fig. 2b–d) present a window for exploiting the malaria parasite enzyme for structure-based inhibitor discovery—consistent with recent high-throughput chemical library screening data<sup>31</sup>.


**Parasite and erythrocyte localization of *PfTyrRS*.** Confocal microscopy was performed using protein-A purified IgG fraction of rabbit antibodies that were raised against recombinant *PfTyrRS*. Our localization data show that *PfTyrRS* is present in all three stages of asexual parasite life cycle: rings, trophozoites and schizonts (Fig. 3a; Supplementary Movies 1, 2 and 3 based on z-stacked confocal analyses of rings, trophozoites and schizonts, respectively—DAPI is in blue and *PfTyrRS* in green). Closer examination of *PfTyrRS* localization in infected erythrocytes during trophozoite and schizont stages revealed possible secretion of *PfTyrRS* into infected red blood cell (iRBC), despite absence of an export



**Figure 3 | Cellular localization of *PfTyrRS*.** (a) Confocal microscopy of *P. falciparum* asexual stages—rings, trophozoites and schizonts using anti-sera raised in rabbits against *PfTyrRS*. Scale bar in red corresponds to a size of 5  $\mu$ m (b) Confocal microscopy using anti-GFP antibody (green) in *PfTyrRS*-GFP transgenic parasite cell lines. Parasite nucleus was stained with DAPI (blue) in each case. Scale bar in red corresponds to a size of 5  $\mu$ m. (c) Enhanced chemi-luminescence of parasite culture supernatants using antibodies against *PfTyrRS*, *PfDTD*, *PfMSP1* and *Pf falcipain 2* and (d) Enhanced chemi-luminescence of parasite culture supernatants using anti-GFP antibody.

signal in *PfTyrRS* sequence (Fig. 3a). Similar results were obtained using *PfTyrRS*-GFP fusion parasite transgenic cell lines (Fig. 3b). We therefore tested whether secretion of *PfTyrRS* occurred from schizonts at time of iRBC rupture. To address this, culture supernatants of infected RBCs were separated on SDS-PAGE, and western blotting was performed using anti-*PfTyrRS* antisera (Fig. 3c). This experiment indicated a band of ~42 kDa in iRBC medium that corresponds to the molecular size of *PfTyrRS*. As controls, the parasite-secreted MSP1 and non-secreted proteins like DTD<sup>32,33</sup> and falcipain 2 were also used (Fig. 3c). We also performed western blot analysis using anti-GFP antibody on *PfTyrRS*-GFP parasite cell line supernatants. *PfTyrRS*-GFP fusion protein band of expected molecular weight (70 kDa) was clearly seen in iRBCs supernatants but not in supernatants from uninfected RBCs controls (Fig. 3d). These experiments suggest that *PfTyrRS* is expressed in all asexual parasite stages, and that it is exported to the host erythrocyte cytosol, from where it is released into blood plasma on iRBC rupture.

***PfTyrRS* interaction with host immune cells.** Release of *PfTyrRS* from iRBCs and the presence of an exposed and conformationally competent ELR motif persuaded us to address directly the binding of TyrRS to host immune cells. We performed an *in vivo* experiment where mice were infected with *Plasmodium yoelii* (XNL). Subsequently, spleen cells containing peripheral blood mononuclear cells (PBMCs) were isolated from these infected mice and then presence of native TyrRS was tested using anti-TyrRS-specific antibodies by flow cytometry (Fig. 4a). We observed specific TyrRS binding to mouse macrophages and dendritic cells, among others (Fig. 4a). A corresponding *in vitro* experiment using human PBMCs also showed specific interaction of *PfTyrRS* with human macrophages and, to a lesser degree, with dendritic cells (Fig. 4b). To validate these observations further, we assessed binding of *PfTyrRS* to mouse and human immune cells using confocal microscopy (Fig. 4c,d). We detected both binding and internali-




**Figure 4 | TyRS interaction with PBMCs *in vivo* and *in vitro*.** (a) FACS-based binding of mouse PBMCs with anti-*PfTyRS* antibodies in an *ex vivo* experiment. Left panel shows gating; middle panel shows TyRS binding in immune cells tested in both uninfected and infected mice. Overlay histograms are derived from the TyRS expression dot plots wherein solid grey histogram is uninfected and the black bold line represents data for infected mice. Data are cumulative of two independent experiments. (b) Binding of *PfTyRS* to human PBMCs showing specific interaction with human macrophages and dendritic cells. Left panel shows gating; middle panel shows *PfTyRS* binding to various immune cells. The overlay histogram is derived from *PfTyRS*-binding dot plots wherein solid grey histogram is without *PfTyRS* and black solid line is with *PfTyRS*. Confocal images of binding and internalization of *PfTyRS* into (c) mouse dendritic cells (top panel), mouse macrophages (bottom panel) and (d) human macrophages. In (d) along with wild-type *PfTyRS* (green), the controls of pre-immune sera, ELR/AAA mutant *PfTyRS*, and primary/secondary antibodies alone (that is, no added *PfTyRS*) are shown. For nucleus visualization, DAPI (blue) localization is also shown. The red scale bar in confocal images corresponds to a size of 15  $\mu\text{m}$ .

zation of *PfTyRS* by host macrophages. Supplementary Movie 4 is based on Z-stacking of these confocal images where macrophages are stained for nucleus (DAPI, blue) and for *PfTyRS* (in

green). These data led us to hypothesize an ELR-motif-mediated interaction of *P. falciparum* tyrosyl-tRNA synthetase with human macrophages (Fig. 4c,d).


**Triggering of cytokine secretion by *PfTyrRS*.** Our observations on interaction of *PfTyrRS* with host immune cells prompted us to test whether the ELR motif present in *PfTyrRS* could enable it to trigger release of cytokines from macrophages. We tested this hypothesis by incubating mouse and human macrophage cell lines with recombinant wild-type *PfTyrRS*, with a mutant ELR/AAA-*PfTyrRS*, with lipopolysaccharide (LPS) (as positive control), with media alone and PfDTD (last two as negative controls). In these studies, the amounts of *PfTyrRS* used were in nanomolar (nM) concentration ranges, similar to amounts used in studies with human mini-TyrRS<sup>9–13</sup>. Time kinetic analysis using ELISA revealed maximal production of the inflammatory cytokines TNF- $\alpha$ , IL-6 and IL-1( $\alpha$  and  $\beta$ ) within 6 hours of culture (Tukey's test— $P < 0.001$ ) (Fig. 5a,b), but not of IL-10 or IL-12 (Fig. 5c). The cytokine release mediated by *PfTyrRS*

was dose-dependent, and occurred as early as 4 hours post-incubation of macrophages with *PfTyrRS* (Fig. 5d). Interestingly, the mutant *PfTyrRS* (where ELR was replaced with AAA sequence) did not trigger cytokine release from macrophages and behaved similar to the control proteins PfDTD<sup>32,33</sup> or PfSerRS. In all experiments, LPS was used as a positive control, and all proteins used in these experiments were confirmed to be endotoxin free (Methods). We also observed that *PfTyrRS* that had been immunoprecipitated from parasite culture supernatants was equally capable of triggering release of TNF- $\alpha$  and IL-6 from human macrophage ThP1 cell lines (Fig. 5e). Finally, pre-incubation of *PfTyrRS* with anti-*PfTyrRS* antibodies substantially blocked TNF- $\alpha$  (Tukey's test— $P < 0.05$ ) and IL-6 production (Tukey's test— $P < 0.01$ ) from human macrophages (Fig. 5e), suggesting specific, motif-based *PfTyrRS* interaction with human macrophages.



**Potential receptor(s) for *PfTyrRS* on human macrophages.** To identify a receptor for *PfTyrRS* on macrophages, we pre-incubated human macrophages with anti-CXCR1/2 and anti-*PfTyrRS* antibodies, and tested whether antibody-mediated receptor or protein blockades inhibited *PfTyrRS*-macrophage interaction (Fig. 6a). Specific antibody-mediated blocking of CXCR2 receptor (Tukey's test— $P < 0.05$ ), but not the CXCR1 receptor, on human macrophages reduced *PfTyrRS* binding by ~twofold (Fig. 6a). Blocking of *PfTyrRS* with anti-*PfTyrRS* antibodies also reduced binding of the protein to macrophages (Tukey's test— $P < 0.05$ ) (Fig. 6a). Furthermore, blockage of *PfTyrRS*-macrophage interactions using either anti-CXCR2 or anti-*PfTyrRS* antibodies also significantly reduced the release of TNF- $\alpha$  (Tukey's test— $P < 0.05$ ) and IL-6 (Tukey's test— $P < 0.001$ ) from human macrophages (Fig. 6b). To further probe the significance of ELR motif in binding of *PfTyrRS* to macrophages, we tested inhibition of *PfTyrRS*-macrophage interaction using peptides in which the wild-type *PfTyrRS* ELR peptide sequence (DELRV) was mutated residue-wise to DELAV, DAAAV and DELKL. Fluorescence-activated cell sorting (FACS)-based binding studies of *PfTyrRS* in presence of 100 nM of these peptides showed a significant reduction in binding with only the DELRV peptide sequence (Fig. 6c). The DELKL peptide was less competent in competing whereas the other two peptides did not compete at all (Fig. 6c). Additionally, the *PfTyrRS*-triggered release of TNF- $\alpha$  and IL-6 from human macrophages was significantly reduced in presence of

**Figure 5 | Effect of *PfTyrRS* on mouse macrophages.** (a) Cytokines levels were measured using BioPlex kit (Bio-Rad) and the secretion profiles of TNF- $\alpha$  and IL-6 using mouse macrophages were measured at different time points. Media alone, PfDTD/PfSerRS enzymes and ELR-AAA mutant of *PfTyrRS* were used as negative controls. LPS was used as positive control in all experiments. (b) Identical experiment as in (a) except that the human macrophage cell line ThP1 was used. This experiment has the extra negative control of PfSerRS. (c) Secretion profiles of extra cytokines (IL-1, IL-10 and IL-12) that are secreted from human macrophages on exposure to *PfTyrRS*. (d) Dose-dependent increase in secretion of TNF- $\alpha$  and IL-6 when increasing concentrations of *PfTyrRS* were used with human macrophages. (e) Cytokine secretion profiles using *P. falciparum* culture supernatants alone (Sup), supernatants incubated with anti-TyrRS antibody (Sup +  $\alpha$ TyrRS), parasite culture supernatant-immunoprecipitated *PfTyrRS* (PD-TyrRS) and finally parasite culture supernatant -immunoprecipitated *PfTyrRS* with its antibody (PD-TyrRS +  $\alpha$ TyrRS). TNF- $\alpha$  and IL-6 secretion is clearly enhanced significantly when immunoprecipitated *PfTyrRS* (PD-TyrRS) is used. Triggering activity of *PfTyrRS* (PD-TyrRS) is blocked when pre-incubated with anti-*PfTyrRS* antibodies, indicating specific activation of macrophages with native *PfTyrRS* (PD-TyrRS). Experiments were repeated three times and error bars indicate standard deviation. Tukey's test was performed and  $P$ -values are shown such that the end points of the lines below  $P$ -value represent the datasets that were compared.




**Figure 6 | Potential *PfTyrRS* receptor on human macrophages.** (a) FACS analysis of *PfTyrRS* binding to human macrophages. *PfTyrRS* binding to macrophages is reduced when macrophages had been pre-incubated anti-CXCR2 or with anti-*PfTyrRS* antibodies. Binding was not reduced significantly with anti-CXCR1 antibodies. Overlay histograms show binding of *PfTyrRS* to the surface of human macrophages (black line) with unstained controls (grey solid) as background. (b) Cytokine secretion assays for TNF- $\alpha$  and IL-6 using human macrophages and anti-CXCR1, anti-CXCR2 and anti-*PfTyrRS* antibodies. Secretion of these pro-inflammatory cytokines is reduced when anti-CXCR2 and anti-*PfTyrRS* antibodies were pre-incubated with human macrophages. (c) FACS analysis of *PfTyrRS* binding to human macrophages using four different ELR-mutant peptides in competition assays. Overlay histograms show *PfTyrRS* surface staining (black line) with unstained control (grey solid) as background. (d) Cytokine secretion assays for TNF- $\alpha$  and IL-6 using human macrophages and various ELR-mutant peptides. No significant difference was observed for mutant peptides in these assays. Experiments were repeated three times and the error bars indicate the standard deviation. Tukey's test was performed and *P*-values are shown such that the end points of the lines below *P*-value represent the datasets that were compared.

DELRV peptide (Tukey's test— $P < 0.05$ ) (Fig. 6d). These data, along with our observation that the 'ELR/AAA' *PfTyrRS* mutant does not bind to human macrophage cells (Fig. 4c,d), strongly highlight a role for ELR motif in *PfTyrRS* interactions with human macrophages. We therefore conclude that ELR-motif-based *PfTyrRS* binding likely

occurs using specific receptors on human macrophages, and that this binding leads to very specific host immune system activation.

***PfTyrRS*-stimulated macrophage upregulate ICAM-1 and VCAM-1.** *P. falciparum* cytoadherence enables parasite seques-





**Figure 7 | *PfTyrRS* stimulation of macrophages and subsequent upregulation of endothelial receptors ICAM-1 and VCAM-1.** (a) HUVEC cells (Hu) were incubated with *PfTyrRS* alone, *PfDTD* (negative control protein (CORL), macrophage cells ( $\phi$ ) and TNF- $\alpha$ . Culture supernatants of *PfTyrRS*-induced macrophages and *PfDTD*-induced macrophages were added to HUVEC cell lines. Expression of ICAM-1 and VCAM-1 was measured by FACS using specific conjugated antibodies. Grey bars (left) represent VCAM-1 expression and black bars (right) represent ICAM-1 expression. (b) *PfTyrRS*-induced dose-dependent increase in the expression of ICAM-1. No upregulation of ICAM-1 was observed on addition of ELR/AAA *PfTyrRS* mutant to endothelial cell lines. Bars in black represent *PfTyrRS* treated samples, whereas bars in grey were the samples treated with ELR/AAA mutant protein (c) MTT cytotoxicity assay with dose-dependent response using *PfTyrRS* (red line), ELR/AAA mutant (green line), and control (only cells in blue line) on HUVEC cells. No decrease in cell viability was observed (Tukey's test— $P > 0.05$ ). The optical density on y axis in (c) represents cell survival in an MTT assay. Experiments were repeated three times and the error bars represent standard deviation. Tukey's test was performed and  $P$ -values are shown such that the end points of the lines below  $P$ -value represent the datasets that were compared. NS, not significant.

tration in host tissues, allowing these parasites to avoid splenic clearance which involves degradation and clearing of infected RBCs by the spleen<sup>34–40</sup>. In severe malaria episodes, an increase in the levels of TNF- $\alpha$  is coupled with enhanced expression of endothelial cell receptors such as ICAM-1 (intercellular adhesion molecule-1), VCAM-1 (vascular cell adhesion molecule-1) and E-selectin<sup>34–40</sup>. We therefore tested whether recombinant *PfTyrRS* could modulate expression of endothelial receptors in a static cytoadhesion model assay system. For this 'triggering' to work, *PfTyrRS* had to first initiate enhanced secretion of cytokines like TNF- $\alpha$  from macrophages, and then the increased levels of secreted cytokines would have to induce overexpression of endothelial receptors like ICAM-1 and VCAM-1. As our experimental data show, this is indeed what *PfTyrRS* was able to achieve (Fig. 7). When HUVECs (primary human umbilical vein endothelial cells) were co-cultured with culture supernatants of *PfTyrRS*-activated macrophages, we found strong upregulation of both ICAM-1 and VCAM-1 receptors (Tukey's test— $P < 0.05$ ) (Fig. 7a). A *PfTyrRS*-induced dose-dependent increase in expression of ICAM-1 was also evident (Fig. 7b). These effects were not due to cell toxicity of *PfTyrRS* on HUVECs (Fig. 7c). These experiments therefore provide fundamental molecular insights and also a tool to dissect the molecular basis of cytoadherence using *PfTyrRS* as a 'trigger'. Increased levels of circulating cytokines in malaria infected individuals may activate the host immune system to check or control very high parasitemia levels, which may prove lethal both to pathogen and host.

## Discussion

One of the key pathogenic mechanisms in the virulence of *P. falciparum* is the phenomenon of cytoadherence, attributed to increased adhesion of infected erythrocytes to blood capillaries<sup>34–42</sup>. In particular, cerebral and placental malaria seem to be dependent on crucial protein–protein interactions that occur between a parasite virulence factors and the endothelial/placental receptors<sup>34–42</sup>. The host immune system is hijacked by parasite-derived factors to assist in cytoadherence, for example, by cytokine-induced increased expression of a range of adhesion molecules<sup>16,18–25</sup>. Numerous field reports on human malaria and mouse model studies have shown that malaria infection alters host cytokine profiles by modulating dendritic cells and macrophages<sup>16,18–25</sup>. This is presumably done to aid in parasite survival and transmission. Elevated cytokine levels have a variety of physiological effects, generally to the detriment of the hosts<sup>16,34–42</sup>. In fact, malaria as a disease has been looked up on as a manifestation of enhanced pro-inflammatory cytokine production in host<sup>16,34–42</sup>. For example, the clinical manifestations of severe malaria can be correlated with induction of strong pro-inflammatory responses in which plasma levels of circulating TNF- $\alpha$ , IFN- $\gamma$  and IL-6 increase significantly<sup>19–21</sup>. Pathways that propel host immune cell activation in malaria remain mysterious in context of parasite-derived protein antigens. The interaction of latter with macrophages and dendritic cells must occur before cytokine induction. So far, studies have identified several such molecular agents<sup>2–22</sup>, but, to our knowledge, no parasite-secreted housekeeping enzyme has been attributed with the ability to trigger enhanced secretion of cytokines like TNF- $\alpha$  and IL-6. In this context, we find it very interesting that the levels of TNF- $\alpha$  secreted from immune cells reported in previous studies<sup>22–25</sup> are similar to or lower than those we report with *PfTyrRS*. A comparison of secreted TNF- $\alpha$  levels ( $\text{pg ml}^{-1}$ ) is illuminating—using 100 nM *PfTyrRS*: 1,000–1,300  $\text{pg ml}^{-1}$ , 50–400 nM GPIs: 800–1,300  $\text{pg ml}^{-1}$ ,  $\sim\mu\text{g ml}^{-1}$  DNA-protein complexes: 500–600  $\text{pg ml}^{-1}$  and 30–100  $\mu\text{M}$  hemozoin; 400–600  $\text{pg ml}^{-1}$ ,  $\sim 500,000$  microparticles; 150–200  $\text{pg ml}^{-1}$ . This comparison indicates importance of *PfTyrRS* as a trigger for excitation of pro-inflammatory cytokine release from host immune cells.

Our corroborative confocal microscopy data not only reveals decoration of host macrophage surfaces with *PfTyrRS* but also its



internalization. We propose that, as a result of *Pf*TyrRS-macrophage interactions, significantly higher amounts of pro-inflammatory cytokines like TNF- $\alpha$ , IL-1 and IL-6 are released. Elevated cytokine levels can have severe effects in hosts and severe malarial anemia (SMA) provides an excellent example of this<sup>45</sup>. Increased circulating TNF- $\alpha$  inhibits erythroblast differentiation and dampens erythropoiesis resulting in worsening SMA symptoms<sup>16–21,45</sup>. Another outcome of higher levels of circulating TNF- $\alpha$  in infected malaria patients is the increase in expression levels of certain endothelial receptors like ICAM-1, VCAM-1 and E-selectin that contribute to cytoadherence in severe malaria<sup>39–42</sup>. Our data based on co-incubation of three components—purified *Pf*TyrRS macrophages and endothelial cells, now provides a system that can be further dissected to investigate molecular and cellular interactions that occur during SMA and cytoadherence. This work therefore provides clues to the possibility of *Pf*TyrRS acting as a malarial toxin that can induce cytokine-mediated disease.

Aminoacyl-tRNA synthetases have a vital role in translating the genetic code. Numerous studies have shown that members of this enzyme family are quite adept at ‘moonlighting’ in terms of possessing extra capabilities that widen their biological attributes<sup>5–8</sup>. Studies have indicated that human tyrosyl-, tryptophanyl- and lysyl-tRNA synthetases can be secreted extracellularly and can mimic cytokines<sup>5–8</sup>. For these extra roles, the human TyrRS and TrpRS require either proteolytic cleavage or alternate splicing to become active<sup>5–9</sup>, whereas LysRS can act like a cytokine without processing<sup>44</sup>. In this light, this is the first report of a human pathogen tRNA synthetase that can also perform moonlighting activity of inducing host immune system to release pro-inflammatory cytokines. In summary, this study suggests that *Pf*TyrRS is secreted from the parasite and deposited proximal to iRBC membrane (despite lack of a ‘PEXEL’ export element<sup>43</sup>). *Pf*TyrRS egress occurs during trophozoite and schizont stages, before iRBC rupture. On iRBC lysis, *Pf*TyrRS is released into blood plasma, where it is potentially free to interact with host cells. We show that *Pf*TyrRS interacts with specific receptor(s) on host macrophages, and that this event is largely mediated by the ELR motif present in *Pf*TyrRS. Finally, we have determined the three-dimensional structure of *Pf*TyrRS in complex with Tyr-AMP, and provide detailed structural comparisons with host counterpart of *Pf*TyrRS. This work therefore not only provides a structural framework for using *Pf*TyrRS-YAP complex structure as a starting point for structure-based drug discovery, but also lays foundation for probing key immunological questions in malaria. The twin abilities of malaria parasite tyrosyl-tRNA synthetase—as a housekeeping protein translation enzyme and as a trigger for pro-inflammatory cytokine release in hosts—highlight this protein as a target for discovery of novel anti-parasitic strategies.

## Methods

**Animal experiments.** Animal experiments were performed in accordance with Institutional Animal Ethics Committee guidelines approved by Department of Biotechnology, Govt of India. This project was approved in a meeting held on 28 October 2009 at ICGB (approval ID: ICGB/IAEC/MAL-50). All mice used were killed ethically by asphyxiation in carbon dioxide according to regulatory body instructions.

**Synthetic tRNA preparation and aminoacylation assay.** Synthetic *Plasmodium falciparum* tRNA clones were obtained according to Sampson and Uhlenbeck<sup>46</sup> by assembling up to 6 oligonucleotides and ligation between HindIII and BamHI sites into pUC19 vector. The tRNAs were obtained by *in vitro* transcription using T7 RNA polymerase according to standard protocols. *In vitro* tRNA aminoacylation assays were performed at 37 °C in 50 mM Tris-HCl pH 7.6, 50 mM KCl, 25 mM MgCl<sub>2</sub>, 5 mM ATP, 0.1 mg ml<sup>-1</sup> BSA, 1 mM DTT, 20  $\mu$ M tyrosine, 0.5 mCi ml<sup>-1</sup> L-[3,5-<sup>3</sup>H]tyrosine and 0.5  $\mu$ M *Pf*TyrRS as reported<sup>47</sup>. Reaction was initiated by addition of pure enzyme and samples of 20  $\mu$ l were spotted onto Whatman 3M discs at varying time intervals (usually 2 min). Radioactivity (corresponding to amino acid ligated to tRNA substrate) was measured by liquid scintillation.

**Protein expression, purification and crystallization.** TyrRS gene (MAL8P1.125), from *P. falciparum* was PCR amplified from complementary DNA and cloned

into pQE30 vector (Qiagen). Four hours post -IPTG (isopropyl 1-thio-D-galactopyranoside, 0.5 mM) induction, the bacterial cell pellet was suspended in buffer containing 50 mM Tris-HCl, 500 mM NaCl, 50 mM imidazole, pH 8.0 and protease inhibitor cocktail. Protein was purified using Ni-NTA beads (Qiagen) and gel filtration chromatography. Pure, dimeric *Pf*TyrRS was concentrated and buffer exchanged into 25 mM Tris-HCl pH 8.0, 150 mM NaCl and 10 mM BME. Diffraction quality crystals using His-tag-free *Pf*TyrRS were grown by hanging drop vapour diffusion method at 20 °C. The droplet size was 1  $\mu$ l of protein (30 mg ml<sup>-1</sup> in 25 mM Tris pH 8.0, 100 mM NaCl, 10 mM BME, 10 mM MgCl<sub>2</sub>, 10 mM ATP and 2 mM L-tyrosine) with 1  $\mu$ l of reservoir solution equilibrated over 200  $\mu$ l of 2.4 M sodium malonate at pH 6.0.

**Data collection and structure determination.** A single crystal was transferred to cryoprotectant reagent (paratone oil) for a short period (5–10 s) before freezing in a stream of cooled nitrogen gas. Data were collected at 100 K using Cu K $\alpha$  radiation ( $\lambda = 1.54 \text{ \AA}$ ) on a MAR345 image-plate detector mounted on a Rigaku MicroMax-007 rotating-anode X-ray generator. A total of 700 frames were collected in 1 $^\circ$  oscillation steps with 5 min exposure per frame, and data were processed with HKL2000 (ref. 48). The structure was solved by molecular replacement in MOL-REP<sup>49</sup> using cytoplasmic mini-HsTyrRS (PDB: 1N3L) as a starting model. Iterated manual model building and refinement was done using COOT<sup>50</sup> and phenix.refine<sup>51</sup>. The structural representations in this paper were prepared with Chimera<sup>52</sup> and PyMOL (http://www.pymol.org).

**Cell-binding assays.** For *in vitro* localization experiments, synchronous parasite cultures of *P. falciparum* 3D7 were washed with PBS, fixed in solution using 4% paraformaldehyde and 0.0075% glutaraldehyde for 20 min, permeabilized with 0.1% Triton X-100 for 10 min and then treated for 10 min with 0.1 mg ml<sup>-1</sup> sodium borohydride in PBS. Each step was followed by a brief PBS wash<sup>53</sup>. Cells were blocked in 3% BSA, PBS for 1 h, washed in PBS and incubated overnight with protein-A column purified rabbit anti-*Pf*TyrRS antibodies (1:150 dilution in PBS containing 3% BSA) at 4 °C. After three washes (10 min each) with PBS, the cells were incubated with Alexa Fluor<sup>488</sup>-conjugated anti-rabbit secondary antibody (1:250 dilution in PBS containing 3% BSA) for 2 h at room temperature and allowed to settle onto poly-D-lysine (100 mg ml<sup>-1</sup>)-coated coverslips. These were then washed three times in PBS and mounted in antifade with DAPI (Molecular Probes). Spleen cells were purified from *P. yoelii*-infected mice and PBMCs were isolated from both mouse and human blood as described earlier<sup>54</sup>. For the *in vivo* experiment, C57BL/6 mice were infected with ~1 million *P. yoelii* (17XNL strain) in the form of parasitized RBCs intraperitoneally. Fifteen days after infection, the spleens were collected from infected and age- and sex-matched uninfected control mice. Spleens were crushed and lymphocytes were isolated and stained for flow cytometry by standard procedures. The cells were fixed with Cytofix (BD Biosciences) and permeabilized with 1X Cytoperm (BD Biosciences) for intracellular TyrRS staining. The data was acquired on BD FACS Canto II (BD Biosciences) and analysed on by FlowJo software (TreeStar). Human PBMCs were isolated using BD Vacutainer CPT tubes (BD Biosciences) by centrifugation at 1,600 g per 25 min/RT/no brake. The cells were thoroughly washed and resuspended in complete RPMI containing 10% FCS in a 24-well plate, and 100 nM purified *Pf*TyrRS protein was added for 3 h at 37 °C (95% humidity, 5% CO<sub>2</sub>). Analytical flow cytometry was performed by direct staining for specific populations of immune cells with fluorescently conjugated antibodies and biotin-conjugated anti-*Pf*TyrRS antibody (1:150 dilution in PBS). The data obtained on BD FACS Canto II (BD Biosciences) was analysed using FlowJo software (TreeStar). *In vitro* binding of *Pf*TyrRS to various immune cells was performed by FACS using standard protocols. Dendritic cells and macrophage ThP1 cells were cultured on coverslips in 24-well plates (Gibson) and maintained in DMEM medium containing 20% (v/v) FBS and 1% antibiotics (Gibco). *Pf*TyrRS and other control proteins were incubated with cells at several concentrations for 5 min to 2 h at 4 °C. Cells were washed twice in PBS and incubated with 2% formaldehyde (Sigma) for 15 min and followed by incubation for 10 min with 0.1% saponin (Sigma). Primary and secondary antibodies were added as per manufacturer's instructions (Molecular Probes). Fluorescence microscopy was performed on Nikon A1R confocal laser scanning microscope.

**Western blots.** *P. falciparum* (schizont stage) -infected human erythrocytes (1.5 $\times$ 10<sup>7</sup> parasites per ml) were enriched and parasites were cultured for 6–10 h to allow the maturation of schizonts, release of merozoites and their material<sup>54</sup>. Culture supernatant was collected in the presence of protease inhibitor cocktail after two rounds of centrifugation of 1,000 g for 15 min followed by 10,000 g for 20 min before freezing at -70 °C. Culture supernatant was subsequently used for western blotting using different antibodies against *Pf*DTT (dilution, 1:500), *Pf*falcipain 2 (dilution, 1:1,000), *Pf*MSP-1 (dilution, 1:1,000) and *Pf*TyrRS (dilution, 1:500).

**Cytokine secretion assays.** Raw-264.7, J774 murine cells, Dendritic cells (isolated from femur bone marrow of the mice C57BL/6) and human THP1 macrophage cells (3 $\times$ 10<sup>4</sup>) were cultured in RPMI medium with 10% FBS and 1% antibiotics in 24-well format plates. Proteins were passed through polymyxin

beads (Sigma) before assays. LPS, *PfTyrRS* and control proteins were added to the medium at different concentrations. 100  $\mu$ l of culture medium was collected and centrifuged after every 4, 24 and 48 h. Cytokines in the culture supernatant were detected by a Luminex microbead-based multiplexed assay (Bio-Plex manager 5.0) using commercially available kits according to the manufacturer's protocol (Bio-Plex, Bio-Rad). All proteins were tested for endotoxin contaminations and passed through polymyxin beads (Sigma). LAL (Limulus Amebocyte Lysate) assay was performed to confirm that the proteins were endotoxin-free before each assay.

***PfTyrRS* interaction with human macrophages.** Cultured human macrophages cells were mixed with *PfTyrRS* in absence or presence of different antibodies, namely anti-*PfTyrRS*, anti-CXCR1 and anti-CXCR2. Binding of *PfTyrRS* was tested using standard FACS protocols. In related experiments, cytokine profiling of these human macrophages was also done, either in absence or presence of antibodies used above. Cytokines released in culture supernatants were detected by a Luminex microbead-based multiplexed assay (Bio-Plex manager 5.0) using commercially available kits and according to the manufacturer's protocol (Bio-Plex, Bio-Rad). Similar experiments were performed using various wild-type and mutant ELR-based peptides. Human macrophages (ThP1 cells) were incubated with 100 nM of these peptides before addition of *PfTyrRS*. FACS and cytokine profiling were again done on all these samples as for the antibody treatment experiments.

**Upregulation of endothelial cell receptors.** Monocytes were obtained from buffy coat by Lymphoprep (Axis-Shield) gradient centrifugation, followed by adhesion-mediated purification on tissue culture plastic. The cells were cultured for 3 days in RPMI-164 medium (Sigma) supplemented with 2 mM L-glutamine and 10% FBS to differentiate into macrophage. The recombinant *PfTyrRS* or control proteins were added at a concentration of 1  $\mu$ l ml<sup>-1</sup> on day 3, and cells were cultured continuously for 3 days. The culture supernatant was collected and centrifuged at 13,000 g for 10 min to remove any debris; the supernatant was used for co-culture with endothelium. Primary pooled human umbilical vein endothelial cells (HUVEC) were obtained from Promocell. Cells were maintained in complete growth medium supplied by Promocell, according to the company's instructions. To reduce variation, only cells at passage five to six were used. HUVEC were grown on 1% gelatin (Sigma) coated on 24-well plates with appropriate growth medium, until confluent. Then, the culture medium was replaced with either fresh medium alone, medium containing recombinant *PfTyrRS* or control protein (added at concentration 100 nM) or macrophage culture supernatants. These were incubated at 37 °C in 5% CO<sub>2</sub> for 16 h. Endothelial cell markers were measured by fluorescence-activated cell sorting (FACSscan; Becton Dickinson). Specific fluorescence-conjugated antibodies, including APC Mouse anti-human CD54 (ICAM-1) and PE Mouse anti-human CD106 (VCAM-1) (Becton Dickinson), were used in this study. Nonspecific fluorescence was assessed using corresponding isotype control antibodies. The expression of endothelial surface proteins ICAM-1 and VCAM-1 was indicated by geometric mean of the fluorescence intensity. *PfTyrRS* was subsequently used in a dose-dependent experiment for testing increased expression of ICAM-1, using the protocols described above.

***PfTyrRS*-GFP microscopy.** The gene was amplified with genomic DNA of *P. falciparum* using following primers: forward-5'-CTCGAGATGATAATAT TAAAGGTTTATTTA-3' reverse-5'-GGTACCTTTTATTATATAGAAATAAC TTGTC-3' and cloned into pGEM-T vector (Promega). The insert was released from pGEMT and cloned between XhoI and KpnI in pGluc vector (Amersham). Transformations and clone propagation was done in Dh5 $\alpha$  cells. Transfection of vectors into the parasite was done, as described earlier<sup>55</sup>. GFP-expressing infected erythrocytes were studied live or fixed at ambient temperature. Cells were viewed with a UPlanSApo  $\times$ 100 1.4 oil objective on a Olympus IX81 Live Cell Imaging Inverted Microscope equipped with an Olympus F-View camera and primarily processed with analysisSIS LS Research software package. Captured images were then further processed using Photoshop and ImageJ. Pictures were adjusted to gain optimal contrast to visualize features of interest.

**MTT assays.** HUVEC cells at passage 5 were seeded at a concentration of  $2 \times 10^4$  cells per well (in 100  $\mu$ l) and allowed to attach for 24 h on 1% gelatine (Sigma) coated on 96-well plates in complete growth medium under standard conditions (5% CO<sub>2</sub>, 95% humidity, 37 °C). Then, the cells were exposed to *PfTyrRS* at the concentrations indicated along with mutant *PfTyrRS* or HUVEC alone. The exposure time was 24 hours. Afterwards, the cell culture medium was withdrawn and in each well 10  $\mu$ l MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma] stock solution (5 mg ml<sup>-1</sup>) was added, followed by an incubation period of 4 h. Afterwards, 100  $\mu$ l per well stop solution (40 g SDS per 200 ml 50% DMF (NN-Dimethylformide, Sigma)) was added, followed by an incubation step overnight (37 °C). MTT metabolism as parameter for metabolic activity was recorded spectrophotometrically by Varioskan at 570 nm.

**Statistical analyses.** Data are derived from multiple independent experiments done in triplicates. Statistical analyses were conducted using SPSS software and values are presented as mean  $\pm$  s.d. Significant differences between groups were determined by ANOVA followed by Tukey's multiple comparison test (SPSS software). A value of  $P < 0.05$  was accepted as an indication of statistical significance.

## References

1. Ibba, M. & Söll, D. Aminoacyl-tRNA synthesis. *Annu. Rev. Biochem.* **69**, 617–650 (2000).
2. Ibba, M. & Söll, D. The renaissance of aminoacyl-tRNA synthesis. *EMBO Rep.* **2**, 382–387 (2001).
3. Eriani, G., Delarue, M., Poch, O., Gangloff, J. & Moras, D. Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs. *Nature* **347**, 203–206 (1990).
4. Burbaum, J. J. & Schimmel, P. Structural relationships and the classification of aminoacyl-tRNA synthetases. *J. Biol. Chem.* **266**, 16965–16968 (1991).
5. Brown, M. V., Reader, J. S. & Tzima, E. Mammalian aminoacyl-tRNA synthetases: cell signaling functions of the protein translation machinery. *Vascul. Pharmacol.* **52**, 21–26 (2010).
6. Bhatt, T. K. *et al.* A genomic glimpse of aminoacyl-tRNA synthetases in malaria parasite *Plasmodium falciparum*. *BMC Genomics* **10**, 644 (2009).
7. Guo, M., Yang, X. L. & Schimmel, P. New functions of aminoacyl-tRNA synthetases beyond translation. *Nat. Rev. Mol. Cell Biol.* **11**, 668–674 (2010).
8. Guo, M., Schimmel, P. & Yang, X. L. Functional expansion of human tRNA synthetases achieved by structural inventions. *FEBS Lett.* **584**, 434–442 (2010).
9. Wakasugi, K. & Schimmel, P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. *Science* **284**, 147–151 (1999).
10. Wakasugi, K., Slike, B. M., Hood, J., Ewalt, K. L., Cheresch, D. A. & Schimmel, P. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. *J. Biol. Chem.* **277**, 20124–20126 (2002).
11. Yang, X. L. *et al.* Gain-of-function mutational activation of human tRNA synthetase procytokine. *Chem. Biol.* **14**, 1323–1333 (2007).
12. Kapoor, M., Otero, F. J., Slike, B. M., Ewalt, K. L. & Yang, X. L. Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase. *Chem. Biol.* **16**, 531–539 (2009).
13. Yang, X. L., Skene, R. J., McRee, D. E. & Schimmel, P. Crystal structure of a human aminoacyl-tRNA synthetase cytokine. *Proc. Natl Acad. Sci. USA* **99**, 15369–15374 (2002).
14. World Health Organization (2009) WHO World malaria report, [http://www.who.int/malaria/world\\_malaria\\_report\\_2009/en/index.html](http://www.who.int/malaria/world_malaria_report_2009/en/index.html).
15. Milner, D. A. Jr. Rethinking cerebral malaria pathology. *Curr. Opin. Infect. Dis.* **23**, 456–463 (2010).
16. Clark, I. A., Budd, A. C., Alleva, L. M. & Cowden, W. B. Human malarial disease: a consequence of inflammatory cytokine release. *Malaria J.* **5**, 85 (2006).
17. Riley, E. M., Wahl, S., Perkins, D. J. & Schofield, L. Regulating immunity to malaria. *Parasite Immunol.* **28**, 35–49 (2006).
18. Corrigan, R. A. & Rowe, J. A. Strain variation in early innate cytokine induction by *Plasmodium falciparum*. *Parasite Immunol.* **32**, 512–527 (2010).
19. Robinson, L. J. *et al.* Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical *Plasmodium falciparum* malaria in children from Papua New Guinea. *Infect. Immun.* **77**, 3033–3043 (2009).
20. Doodoo, D., Omer, F. M., Todd, J., Akanmori, B. D., Koram, K. A. & Riley, E. M. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production *in vitro* predict clinical immunity to *Plasmodium falciparum* malaria. *J. Infect. Dis.* **185**, 971–979 (2002).
21. Brustoski, K. *et al.* IFN- $\gamma$  and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated *Plasmodium falciparum* malaria. *J. Immunol.* **174**, 1738–1745 (2005).
22. Coban, C. *et al.* Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. *J. Exp. Med.* **201**, 19–25 (2005).
23. Krishnegowda, G. *et al.* Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of *Plasmodium falciparum*: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. *J. Biol. Chem.* **280**, 8606–8616 (2005).
24. Couper, K. N. *et al.* Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. *PLoS Pathog.* **6**, e1000744 (2010).
25. Wu, X., Gowda, N. M., Kumar, S. & Gowda, D. C. Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. *J. Immunol.* **184**, 4338–4348 (2010).
26. Fechter, P., Rudinger-Thirion, J., Théobald-Dietrich, A. & Giegé, R. Identity of tRNA for yeast tyrosyl-tRNA synthetase: tyrosylation is more sensitive to identity nucleotides than to structural features. *Biochemistry* **39**, 1725–1733 (2000).
27. Quinn, C. L., Tao, N. & Schimmel, P. Species-specific microhelix aminoacylation by a eukaryotic pathogen tRNA synthetase dependent on a single base pair. *Biochemistry* **34**, 12489–12495 (1995).
28. Tsunoda, M. *et al.* Structural basis for recognition of cognate tRNA by tyrosyl-tRNA synthetase from three kingdoms. *Nucleic Acids Res.* **35**, 289–4300 (2007).

29. Bonnefond, L. *et al.* Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features. *Structure* **15**, 1505–1516 (2007).
30. Zhao, X., Town, J. R., Li, F., Zhang, X., Cockcroft, D. W. & Gordon, J. R. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels. *J. Immunol.* **182**, 3213–3222 (2009).
31. Gamo, F. J. *et al.* Thousands of chemical starting points for antimalarial lead identification. *Nature* **465**, 305–310 (2010).
32. Bhatt, T. K., Yogavel, M., Wydau, S., Berwal, R. & Sharma, A. Ligand-bound structures provide atomic snapshots for the catalytic mechanism of D-amino acid decylase. *J. Biol. Chem.* **285**, 5917–5930 (2010).
33. Yogavel, M., Khan, S., Bhatt, T. K. & Sharma, A. Structure of D-tyrosyl-tRNA<sup>tyr</sup> decylase using home-source Cu K $\alpha$  and moderate-quality iodide-SAD data: structural polymorphism and HEPES-bound enzyme states. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 584–592 (2010).
34. López, J. A. Malignant malaria and microangiopathies: merging mechanisms. *Blood* **115**, 1317–1318 (2010).
35. Medina, I. M. & Turner, G. D. Human cerebral malaria and the blood-brain barrier. *Int. J. Parasitol.* **36**, 555–568 (2006).
36. Wilson, N. O. *et al.* Soluble factors from *Plasmodium falciparum*-infected erythrocytes induce apoptosis in human brain vascular endothelial and neuroglia cells. *Mol. Biochem. Parasitol.* **162**, 172–176 (2008).
37. Combes, V., Coltel, N., Faille, D., Wassmer, S. C. & Grau, G. E. Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. *Int. J. Parasitol.* **36**, 541–546 (2006).
38. Pasternak, N. D. & Dzikiowski, R. PfEMP1: an antigen that plays a key role in the pathogenicity and immune evasion of the malaria parasite *Plasmodium falciparum*. *Int. J. Biochem. Cell Biol.* **41**, 14631466 (2009).
39. Tripathi, A. K., Sha, W., Shulaev, V., Stins, M. F. & Sullivan, D. J. Jr. *Plasmodium falciparum*-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. *Blood* **114**, 4243–4252 (2009).
40. Stevenson, M. M. & Urban, B. C. Antigen presentation and dendritic cell biology in malaria. *Parasite Immunol.* **28**, 5–14 (2006).
41. Diouf, I. *et al.* IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by *Plasmodium falciparum*. *J. Reprod. Immunol.* **74**, 152–162 (2007).
42. Francischetti, I. M., Seydel, K. B. & Monteiro, R. Q. Blood coagulation, inflammation, and malaria. *Microcirculation* **15**, 81–107 (2008).
43. Goldberg, D. E. & Cowman, A. F. Moving in and renovating: exporting proteins from *Plasmodium* into host erythrocytes. *Nat. Rev. Microbiol.* **8**, 617–621 (2010).
44. Park, S. G. *et al.* Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. *Proc. Natl Acad. Sci. USA* **102**, 6356–6361 (2005).
45. Haldar, K. & Mohandas, N. Malaria, erythrocytic infection, and anemia. *Hematology Am. Soc. Hematol. Educ. Program* 87–93 (2009).
46. Sampson, J. R. & Uhlenbeck, O. C. Biochemical and physical characterization of an unmodified yeast phenylalanine transfer RNA transcribed *in vitro*. *Proc. Natl Acad. Sci. USA* **85**, 1033–1037 (1988).
47. Schulman, L. H. & Pelka, H. Anticodon loop size and sequence requirements for recognition of formylmethionine tRNA by methionyl-tRNA synthetase. *Proc. Natl Acad. Sci. USA* **80**, 6755–6759 (1983).
48. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* **276**, 307–326 (1997).
49. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 22–25 (2010).
50. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132 (2004).
51. Adams, P. D. *et al.* PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr. D Biol. Crystallogr.* **58**, 1948–1954 (2002).
52. Pettersen, E. F. *et al.* UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).
53. Tonkin, C. J. *et al.* Localization of organellar proteins in *Plasmodium falciparum* using a novel set of transfection vectors and a new immunofluorescence fixation method. *Mol. Biochem. Parasitol.* **137**, 13–21 (2004).
54. Haynes, J. D. *et al.* Receptor-like specificity of a *Plasmodium knowlesi* malarial protein that binds to Duffy antigen ligands on erythrocytes. *J. Exp. Med.* **167**, 1873–1881 (1988).
55. Crabb, B. S. *et al.* Transfection of the human malaria parasite *Plasmodium falciparum*. *Methods Mol. Biol.* **270**, 263–276 (2004).

### Acknowledgements

We thank Monika Chugh for help with western blotting of culture supernatants. T.K.B., S.K., M.M.B. and A.S. are supported by Department of Biotechnology and CSIR fellowships. A.G.M. is an ARC Australian Research Fellow. This work in part was conducted under EU MEPHITIS project (Grant Agreement no: HEALTH-F3-2009-223024). Funding for research on malaria tRNA synthetases is provided by a DBT grant to the laboratory.

### Author contributions

T.K.B., S.K., V.D. and M.Y. carried out protein studies, collected localization data, and performed structural analyses along with immunological experiments. T.K.B., S.K., M.Y., A.C. and A.S. analysed all data and wrote the manuscript. M.M.B. performed cloning, purified PfTyrRS and crystallized it. A.S. and A.C. helped with cell biology experiments. N.C. and R.P.L. performed aminoacylation assays. Y.W. and A.G.C. performed endothelial activation assays. A.G.M. and A.T.M. performed PfTyrRS-GFP microscopy.

### Additional information

**Accession codes:** Coordinates and structure factors for PfTyrRS have been deposited in the RCSB Protein Data Bank under accession code 3vgj.

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Bhatt, T. K. *et al.* Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory responses. *Nat. Commun.* 2:530 doi: 10.1038/1522 (2011).